Export financials
Coherus BioSciences (CHRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Coherus BioSciences Balance Sheet 2025-2011 | CHRS
Brief overview of Coherus BioSciences's balance sheet strength
The review uses the five latest available annual reports between 2021 and 2025.
Assets fell from $679.3 million to $258.3 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets and liabilities changed at similar rates, -62% and -66.1%. The funding mix did not shift sharply.
The equity ratio equals 23.6%, with a starting level of 14.4%. Stable cash flow is important under this structure.
Net debt moved below zero to -$85.6 million, reflecting surplus cash over debt.
The cash share moved from 61.4% to 34.4%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$1.4 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Coherus BioSciences's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-85.6 M | -121 M | -101 M | -59 M | -414 M | -538 M | 11 M | 30.7 M | -25.1 M | -23.8 M | -158 M | -150 M | -35.4 M | -12.8 M | - |
Long Term Debt |
1.46 M | 3.29 M | 351 K | 1.42 M | 498 K | 875 K | 178 M | 103 M | 102 M | 100 M | - | - | - | - | - |
Long Term Debt Current |
1.83 M | 1.69 M | 1.42 M | 3.13 M | 2.75 M | 2.57 M | 2.2 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
56.9 M | 298 M | 491 M | 480 M | 416 M | 415 M | 189 M | 105 M | 104 M | 103 M | 113 M | 68.7 M | 36.1 M | 6.09 M | - |
Total Current Liabilities |
140 M | 283 M | 332 M | 139 M | 165 M | 146 M | 115 M | 33.3 M | 28.4 M | 56.4 M | 106 M | 51.8 M | - | - | - |
Total Liabilities |
197 M | 581 M | 823 M | 618 M | 582 M | 561 M | 304 M | 138 M | 132 M | 159 M | 219 M | 120 M | 89.8 M | 17.3 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 1.96 M | 51 M | 24 M | 14.3 M | 2.02 M | - |
Retained Earnings |
-1.38 B | -1.55 B | -1.58 B | -1.34 B | -1.05 B | -763 M | -895 M | -985 M | -775 M | -537 M | -410 M | -187 M | -99.6 M | -46 M | - |
Total Assets |
258 M | 449 M | 630 M | 481 M | 679 M | 842 M | 409 M | 99.5 M | 163 M | 178 M | 212 M | 187 M | 47.4 M | 26.5 M | - |
Cash and Cash Equivalents |
88.9 M | 126 M | 103 M | 63.5 M | 417 M | 541 M | 178 M | 72.4 M | 127 M | 125 M | 158 M | 150 M | 39.6 M | 14.5 M | - |
Book Value |
61 M | -132 M | -193 M | -137 M | 97.7 M | 281 M | 105 M | -38.6 M | 30.5 M | 19.4 M | -6.93 M | 66.8 M | -42.4 M | 9.19 M | - |
Total Shareholders Equity |
61 M | -132 M | -193 M | -137 M | 97.7 M | 281 M | 105 M | -38.6 M | 31.8 M | 20.5 M | -6.21 M | 66.8 M | -97.1 M | -45.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Coherus BioSciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 459 K | - | 1.46 M | - | - | - | 3.29 M | - | - | - | 4.98 M | - | - | - | 3.63 M | - | - | - | 6.75 M | - | - | 8.38 M | 9.07 M | 9.74 M | 10.4 M | 11 M | 10.3 M | 10.8 M | 5.98 M | 6.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
70.2 M | 54.8 M | 55.1 M | 56.9 M | 56.4 M | 56 M | 299 M | 298 M | 297 M | 296 M | 307 M | 491 M | 478 M | 475 M | 476 M | 480 M | 477 M | 428 M | 427 M | 416 M | 291 M | 296 M | 308 M | 415 M | 415 M | 413 M | 190 M | 189 M | 189 M | 183 M | 183 M | 105 M | 105 M | 104 M | 104 M | 104 M | 103 M | 105 M | 103 M | 103 M | 102 M | 205 M | 200 M | 113 M | 79.8 M | 83.2 M | 63.2 M | 68.7 M | 71.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
146 M | 130 M | 187 M | 197 M | 429 M | 320 M | 555 M | 581 M | 593 M | 759 M | 845 M | 823 M | 717 M | 644 M | 599 M | 618 M | 648 M | 569 M | 581 M | 582 M | 611 M | 583 M | 566 M | 561 M | 548 M | 543 M | 309 M | 304 M | 271 M | 244 M | 225 M | 138 M | 129 M | 126 M | 132 M | 132 M | 135 M | 141 M | 151 M | 159 M | 161 M | 313 M | 293 M | 219 M | 162 M | 153 M | 115 M | 120 M | 120 M | 120 M | 120 M | 89.8 M | 89.8 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 669 K | 892 K | 1.38 M | 61.3 M | 49.6 M | 49.6 M | 28.8 M | 31 M | 22.8 M | 22.8 M | 25.2 M | 22.8 M | 22.8 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.48 B | -1.44 B | -1.42 B | -1.38 B | -1.35 B | -1.31 B | -1.61 B | -1.55 B | -1.5 B | -1.49 B | -1.48 B | -1.58 B | -1.5 B | -1.46 B | -1.42 B | -1.34 B | -1.28 B | -1.2 B | -1.15 B | -1.05 B | -1 B | -966 M | -936 M | -763 M | -772 M | -800 M | -859 M | -895 M | -934 M | -981 M | -1 B | -985 M | -922 M | -863 M | -820 M | -775 M | -726 M | -667 M | -612 M | -537 M | -461 M | -545 M | -475 M | -410 M | -358 M | -286 M | -227 M | -187 M | -158 M | -187 M | -187 M | -99.6 M | -99.6 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
171 M | 191 M | 266 M | 258 M | 517 M | 439 M | 371 M | 449 M | 505 M | 675 M | 764 M | 630 M | 584 M | 470 M | 402 M | 481 M | 551 M | 546 M | 593 M | 679 M | 742 M | 740 M | 693 M | 842 M | 804 M | 757 M | 467 M | 409 M | 327 M | 240 M | 186 M | 99.5 M | 141 M | 188 M | 128 M | 163 M | 190 M | 172 M | 227 M | 178 M | 192 M | 251 M | 226 M | 212 M | 202 M | 250 M | 153 M | 187 M | 129 M | 187 M | 187 M | 47.4 M | 47.4 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
53.6 M | 83.2 M | 115 M | 89.1 M | 104 M | 217 M | 82.7 M | 126 M | 98 M | 160 M | 260 M | 103 M | 80.7 M | 73.4 M | 16.6 M | 64 M | 287 M | 276 M | 326 M | 418 M | 361 M | 330 M | 260 M | 542 M | 293 M | 225 M | 194 M | 178 M | 165 M | 107 M | 82.4 M | 73.2 M | 102 M | 131 M | 82.9 M | 128 M | 136 M | 74.2 M | 126 M | 126 M | 160 M | 221 M | 180 M | 159 M | 154 M | 206 M | 115 M | 150 M | 101 M | 150 M | 150 M | 39.6 M | 39.6 M | - | - | 14.5 M | - | - | - | 7.68 M | - | - | - |
Book Value |
25.2 M | 60.8 M | 78.6 M | 61 M | 87.8 M | 120 M | -183 M | -132 M | -88 M | -84.1 M | -81.8 M | -193 M | -134 M | -175 M | -197 M | -137 M | -97.1 M | -22.6 M | 12.6 M | 97.7 M | 131 M | 156 M | 128 M | 281 M | 256 M | 213 M | 157 M | 105 M | 56 M | -3.98 M | -38.5 M | -38.6 M | 12.4 M | 61.8 M | -3.09 M | 30.5 M | 54.9 M | 30.9 M | 77 M | 19.4 M | 31.7 M | -61.9 M | -66.9 M | -6.93 M | 40 M | 96.4 M | 38 M | 66.8 M | 9.18 M | 66.8 M | 66.8 M | -42.4 M | -42.4 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
25.2 M | 60.8 M | 78.6 M | 61 M | 87.8 M | 120 M | -183 M | -132 M | -88 M | -84.1 M | -81.8 M | -193 M | -134 M | -175 M | -197 M | -137 M | -97.1 M | -22.6 M | 12.6 M | 97.7 M | 131 M | 156 M | 128 M | 281 M | 256 M | 213 M | 157 M | 105 M | 56 M | -3.98 M | -38.5 M | -38.6 M | 12.4 M | 61.8 M | -3.09 M | 30.5 M | 54.9 M | 30.9 M | 77 M | 19.4 M | 31.7 M | -61.9 M | -66.9 M | -6.93 M | 40 M | 96.4 M | 38 M | 66.8 M | -152 M | 66.8 M | 66.8 M | -97.1 M | -97.1 M | - | - | -45.5 M | - | - | - | -2.31 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Coherus BioSciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Aldeyra Therapeutics
ALDX
|
$ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
$ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
$ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
$ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
$ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
$ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
$ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
$ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
$ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
$ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
$ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
$ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
$ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
$ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
$ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
$ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
$ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
$ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
$ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
$ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
$ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
$ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
$ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
$ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
$ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
$ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
$ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
$ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
$ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
$ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
$ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
$ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
$ 1.83 | -2.66 % | $ 171 M | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
$ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
$ 2.01 | -7.59 % | $ 11.4 M |